Review



fancd2  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech fancd2
    Fancd2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody/pmc12936848-59-0-2
    Average 93 stars, based on 20 article reviews
    fancd2 - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Staining:

    Article Title: Rab32 protects mitochondrial function by anchoring Fancd2 and mediates the protective effect of penehyclidine hydrochloride against myocardial ischemia-reperfusion injury.
    Article Snippet: Myocardial cell injury resulting from myocardial ischemia and reperfusion is one of the primary drivers behind the onset and progression of heart disease.. Penehyclidine hydrochloride (PHC), a novel selective anti-cholinergic agent, exerts a protective effect against myocardial ischemia-reperfusion injury (MIRI).. Rab32 belongs to the family of small GTPase proteins.

    other:

    Article Title: USP5-mediated CD73 deubiquitination drives osimertinib resistance via PI3K/AKT and glycolysis activation in LUAD
    Article Snippet: FANCD2 , Proteintech , Cat# 28619-1-AP; RRID: AB_2881182.

    Nucleic Acid Electrophoresis:

    Article Title: Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis)
    Article Snippet: ImageJ software was used to measure cell density and assess cell viability. .. Each aliquot of protein sample was run on an SDS-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane for immunoblotting with primary antibodies, including ARID1A (Cell Signaling Technology, #12354S, 1:2000 dilution), Cleaved PARP (Cell Signaling Technology, #5625S, 1:2000 dilution), Cleaved caspase3 (Cell Signaling Technology, #9661S, 1:500 dilution), MDM2 (Cell Signaling Technology, #86934S, 1:1000 dilution), p53 (Cell Signaling Technology, #2527S, 1:2000 dilution), p21 (Cell Signaling Technology, #2947S, 1:2000 dilution), PUMA (Cell Signaling Technology, #98672S, 1:2000 dilution), NOXA (Cell Signaling Technology, #14766S, 1:2000 dilution), Phospho-ATM (Ser1981) (Cell Signaling Technology, #5883T, 1:1000 dilution), Phospho-ATR (Ser428) (Cell Signaling Technology, #2853T, 1:1000 dilution), Phospho-BRCA1 (Ser1524) (Cell Signaling Technology, #9009T, 1:1000 dilution), Phospho-Chk1 (Ser345) (Cell Signaling Technology, #2348T, 1:1000 dilution), Phospho-Chk2 (Thr68) (Cell Signaling Technology, #2197T, 1:1000 dilution), Phospho-p53 (Ser15) (Cell Signaling Technology, #9286T, 1:1000 dilution), Phospho-Histone H2A.X (Ser139) (Cell Signaling Technology, #9718T, 1:1000 dilution), MDM4 (Proteintech, #28747-1-AP, 1:1000 dilution), FANCD2 (Proteintech, # 28619-1-AP, 1:1000 dilution) and β-actin (Cell Signaling Technology, #3700S, 1:4000 dilution) antibodies, followed by horseradish peroxidase-conjugated secondary antibodies (ZEN-Bioscience, 511203). ..

    Membrane:

    Article Title: Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis)
    Article Snippet: ImageJ software was used to measure cell density and assess cell viability. .. Each aliquot of protein sample was run on an SDS-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane for immunoblotting with primary antibodies, including ARID1A (Cell Signaling Technology, #12354S, 1:2000 dilution), Cleaved PARP (Cell Signaling Technology, #5625S, 1:2000 dilution), Cleaved caspase3 (Cell Signaling Technology, #9661S, 1:500 dilution), MDM2 (Cell Signaling Technology, #86934S, 1:1000 dilution), p53 (Cell Signaling Technology, #2527S, 1:2000 dilution), p21 (Cell Signaling Technology, #2947S, 1:2000 dilution), PUMA (Cell Signaling Technology, #98672S, 1:2000 dilution), NOXA (Cell Signaling Technology, #14766S, 1:2000 dilution), Phospho-ATM (Ser1981) (Cell Signaling Technology, #5883T, 1:1000 dilution), Phospho-ATR (Ser428) (Cell Signaling Technology, #2853T, 1:1000 dilution), Phospho-BRCA1 (Ser1524) (Cell Signaling Technology, #9009T, 1:1000 dilution), Phospho-Chk1 (Ser345) (Cell Signaling Technology, #2348T, 1:1000 dilution), Phospho-Chk2 (Thr68) (Cell Signaling Technology, #2197T, 1:1000 dilution), Phospho-p53 (Ser15) (Cell Signaling Technology, #9286T, 1:1000 dilution), Phospho-Histone H2A.X (Ser139) (Cell Signaling Technology, #9718T, 1:1000 dilution), MDM4 (Proteintech, #28747-1-AP, 1:1000 dilution), FANCD2 (Proteintech, # 28619-1-AP, 1:1000 dilution) and β-actin (Cell Signaling Technology, #3700S, 1:4000 dilution) antibodies, followed by horseradish peroxidase-conjugated secondary antibodies (ZEN-Bioscience, 511203). ..

    Western Blot:

    Article Title: Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis)
    Article Snippet: ImageJ software was used to measure cell density and assess cell viability. .. Each aliquot of protein sample was run on an SDS-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane for immunoblotting with primary antibodies, including ARID1A (Cell Signaling Technology, #12354S, 1:2000 dilution), Cleaved PARP (Cell Signaling Technology, #5625S, 1:2000 dilution), Cleaved caspase3 (Cell Signaling Technology, #9661S, 1:500 dilution), MDM2 (Cell Signaling Technology, #86934S, 1:1000 dilution), p53 (Cell Signaling Technology, #2527S, 1:2000 dilution), p21 (Cell Signaling Technology, #2947S, 1:2000 dilution), PUMA (Cell Signaling Technology, #98672S, 1:2000 dilution), NOXA (Cell Signaling Technology, #14766S, 1:2000 dilution), Phospho-ATM (Ser1981) (Cell Signaling Technology, #5883T, 1:1000 dilution), Phospho-ATR (Ser428) (Cell Signaling Technology, #2853T, 1:1000 dilution), Phospho-BRCA1 (Ser1524) (Cell Signaling Technology, #9009T, 1:1000 dilution), Phospho-Chk1 (Ser345) (Cell Signaling Technology, #2348T, 1:1000 dilution), Phospho-Chk2 (Thr68) (Cell Signaling Technology, #2197T, 1:1000 dilution), Phospho-p53 (Ser15) (Cell Signaling Technology, #9286T, 1:1000 dilution), Phospho-Histone H2A.X (Ser139) (Cell Signaling Technology, #9718T, 1:1000 dilution), MDM4 (Proteintech, #28747-1-AP, 1:1000 dilution), FANCD2 (Proteintech, # 28619-1-AP, 1:1000 dilution) and β-actin (Cell Signaling Technology, #3700S, 1:4000 dilution) antibodies, followed by horseradish peroxidase-conjugated secondary antibodies (ZEN-Bioscience, 511203). ..



    Similar Products

    95
    Novus Biologicals fancd2
    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
    Fancd2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody+-+BSA+Free/pmc13650023-29-113-115
    Average 95 stars, based on 1 article reviews
    fancd2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    OriGene sc305556
    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
    Sc305556, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+(NM_033084)+Human+Untagged+Clone/pmc13641737-211-20-21
    Average 94 stars, based on 1 article reviews
    sc305556 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    85
    Thermo Fisher gene exp fancd2 hs00276992 m1
    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
    Gene Exp Fancd2 Hs00276992 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/Gene+Exp%2E+FANCD2%2C+Hs00276992_m1/pm41922714-196-15-33
    Average 85 stars, based on 1 article reviews
    gene exp fancd2 hs00276992 m1 - by Bioz Stars, 2026-11
    85/100 stars
      Buy from Supplier

    93
    Proteintech fancd2
    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
    Fancd2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody/pmc12936848-59-0-2
    Average 93 stars, based on 1 article reviews
    fancd2 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology rad51
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, <t>RAD51,</t> and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Rad51, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody/pmc12964014-41-25-26
    Average 94 stars, based on 1 article reviews
    rad51 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology fancd2
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, <t>FANCD2,</t> RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Fancd2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody/pmc12964014-41-20-21
    Average 94 stars, based on 1 article reviews
    fancd2 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti fancj
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, <t>FANCD2,</t> RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Anti Fancj, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Rabbit+mAb/pmc13006209-83-43-44
    Average 94 stars, based on 1 article reviews
    anti fancj - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti fancd2
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, <t>FANCD2,</t> RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Anti Fancd2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Rabbit+mAb/pmc13006209-83-38-39
    Average 94 stars, based on 1 article reviews
    anti fancd2 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Novus Biologicals anti fancd2
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, <t>FANCD2,</t> RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Anti Fancd2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody+(FI-17)/us12558369-285-24-25
    Average 94 stars, based on 1 article reviews
    anti fancd2 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and FANCD2) and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.

    Journal: Advanced Science

    Article Title: Alkylating Agent–Induced FANCL Impairment Damages Pulmonary Arterial, Venous, and Microvascular Endothelial Cells and Predisposes to PAH/PVOD

    doi: 10.1002/advs.78081

    Figure Lengend Snippet: MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and FANCD2) and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.

    Article Snippet: Primary antibodies for fibronectin (FN, #15613‐I‐AP, Proteintech, Rosemont, IL, USA), Twist (ab50887, Abcam, Cambridge, MA, USA), Vimentin (#5741, Cell Signaling Technology, Danvers, MA, USA), Snail (#ab53519, Abcam, Cambridge, MA, USA), ZO‐1 (21773‐1‐AP, proteintech, Wuhan, China), VEGFR2 (9698, CST, Boston, USA), Slug (YM8357, Immunoway, California, USA), proliferating cell nuclear antigen (PCNA, ab29, Abcam, Cambridge, MA, USA), CD31 (AF3628, R&D Systems, Minneapolis, MN, USA), Cleaved caspase3 (#9664, Cell Signaling Technology, Danvers, MA, USA), Bax (#2772S, Cell Signaling Technology, Danvers, MA, USA), B‐cell lymphoma/leukemia 2 (Bcl‐2, 13–8800, Thermo Fisher Scientific, Rockford, IL, USA), γ‐H2AX (#05‐635, EMD Millipore/Merck, USA), α‐smooth muscle actin (α‐SMA, ab124964 and ab7817, Abcam, Cambridge, MA, USA), FANCL (LS‐C807939, LifeSpan BioSciences, Seattle, WA, USA), FANCD2 (NB100‐182, Novus Biologicals, USA), general control nonderepressible 2 (GCN2, #46041, Cell Signaling Technology, Danvers, MA, USA), and β‐actin (66009‐1‐Ig, Proteintech, Rosemont, IL, USA) were used for immunoblotting, immunofluorescence (IF), and immunohistochemistry (IHC) staining.

    Techniques: Western Blot, Expressing, Tissue, Immunohistochemical staining, Staining, Marker, Immunofluorescence, Analysis, Fluorescence, MANN-WHITNEY, Control

    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.

    Journal: Blood Advances

    Article Title: Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma ∗

    doi: 10.1182/bloodadvances.2025016765

    Figure Lengend Snippet: Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.

    Article Snippet: Western blotting (WB) was performed to evaluate the expression levels of total protein and phospho-specific isoforms using the following antibodies: FANCD2 (Santa Cruz Biotechnology, sc-20022), RAD51 (Santa Cruz Biotechnology, sc-398587), PBEF (Santa Cruz Biotechnology, sc-166946), cleaved Caspase3 (Cell Signaling Technology, 9664s), PARP (Cell Signaling Technology, 9532s), cleaved PARP (Cell Signaling Technology, 5625s), γ-H2AX (Ser139; Cell Signaling Technology, 9718s), p-CHK1 (Ser345; Cell Signaling Technology, 2341s), p53 (Cell Signaling Technology, 2527s), p-ATR (Ser428; Cell Signaling Technology, 2853s), p-ATM (Ser1981; Cell Signaling Technology, 4526s), and p-CHK2 (Thr68; Cell Signaling Technology, 2197s).

    Techniques: Inhibition, In Vivo, Injection, Radio Immunoprecipitation, Control

    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.

    Journal: Blood Advances

    Article Title: Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma ∗

    doi: 10.1182/bloodadvances.2025016765

    Figure Lengend Snippet: Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.

    Article Snippet: Western blotting (WB) was performed to evaluate the expression levels of total protein and phospho-specific isoforms using the following antibodies: FANCD2 (Santa Cruz Biotechnology, sc-20022), RAD51 (Santa Cruz Biotechnology, sc-398587), PBEF (Santa Cruz Biotechnology, sc-166946), cleaved Caspase3 (Cell Signaling Technology, 9664s), PARP (Cell Signaling Technology, 9532s), cleaved PARP (Cell Signaling Technology, 5625s), γ-H2AX (Ser139; Cell Signaling Technology, 9718s), p-CHK1 (Ser345; Cell Signaling Technology, 2341s), p53 (Cell Signaling Technology, 2527s), p-ATR (Ser428; Cell Signaling Technology, 2853s), p-ATM (Ser1981; Cell Signaling Technology, 4526s), and p-CHK2 (Thr68; Cell Signaling Technology, 2197s).

    Techniques: Inhibition, In Vivo, Injection, Radio Immunoprecipitation, Control